Scientific deep-dive

Wegovy 7.2 mg: What the Higher Dose Actually Costs

At 7.2 mg, abnormal skin sensation was reported by 22%, against 6% at 2.4 mg and zero on placebo. Nausea barely moves. The cost of escalating is not where anyone expects it.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·4 citations

There is a higher dose of Wegovy now, and its label carries a number almost nobody is discussing. Dysesthesia (abnormal skin sensation, which the label defines as covering burning, tingling, heightened sensitivity and skin pain) was reported by 22% of people on 7.2 mg, more than one person in five. At 2.4 mg it was 6%. On placebo it was zero.[1] If you are weighing this dose against nausea, you are weighing the wrong side effect.

What the table shows

The label reports the 7.2 mg dose against both 2.4 mg and placebo in the same table. That is unusually useful, because it shows what escalating costs, separately from what the drug costs in general.[1]

Wegovy 7.2 mg (N=1,311) against 2.4 mg (N=304) and placebo (N=303). Section 6.1, Table 4.
EffectPlacebo2.4 mg7.2 mg
Dysesthesia0%6%22%
Nausea13%35%39%
Vomiting6%16%22%
Constipation8%19%20%
Hair loss1%3%6%
Fatigue5%9%11%
Dizziness1%5%6%

Compare the last two columns. Nausea moves four points and constipation one, while dysesthesia moves sixteen and hair loss doubles. The gastrointestinal effects everyone braces for are largely already priced in by 2.4 mg; what the higher dose adds is mostly something else.

Going from 2.4 to 7.2 mg barely changes the nausea. It nearly quadruples the skin symptoms.

What dysesthesia actually means

It is not a familiar word and the label spells out what it is counting: allodynia, burning sensation, dysesthesia itself, hyperesthesia, hyperpathia, pain of skin, and paresthesia.[1] In ordinary language, that is skin that burns, tingles, prickles, feels raw, or hurts at a touch that should not hurt. How it compares across Ozempic, Zepbound and Mounjaro is in GLP-1 skin sensitivity, rash and itching.

This is a sensory nerve symptom, not a gut one, and it sits in a different category from everything else on the list. The label does not say why it happens. It does say what happened next: of 288 people on 7.2 mg who had it, 23% had the dose reduced, 8% paused and 2% stopped; most of those recovered, faster than people who changed nothing, and 18% overall had no recovery reported by the time the trial ended. When 38 people who had recovered went back up to 7.2 mg, it returned in 17.[1]

New or worsening numbness, burning or tingling deserves a conversation rather than tolerance. Nerve symptoms are one of the few side-effect categories where waiting it out is not automatically reasonable, and where the underlying cause matters: diabetes, B12 status and other medicines all produce the same picture. Do not assume it is the dose just because the dose went up.

How you get to this dose at all

The label does not treat 7.2 mg as the destination. It is reached only after at least four weeks of tolerating 2.4 mg, and only where further weight reduction is clinically indicated, and the label asks prescribers to weigh how well the drug is working and how well it is tolerated when picking the dose.[1]

That is narrower than the way higher doses usually get discussed. The label does not present 7.2 mg as a reward for doing well or as the natural end of the ladder. Our titration planner prints the schedule from the label itself.

What the extra dose buys

The FDA approved 7.2 mg, sold as Wegovy HD, in March 2026.[3] The trial behind it, STEP UP, ran 72 weeks. On 7.2 mg, weight fell 18.7%, against 15.6% on 2.4 mg and 3.9% on placebo.[2] The step up bought about three percentage points. The same paper puts dysesthesia at 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% (one person) on placebo, the same pattern the label shows.[2]

It also costs more in money. Novo’s own self-pay pharmacy lists the 7.2 mg pen at a higher monthly price than every 2.4 mg-and-below dose.[4] We keep the dated figures on the price tracker. Three points of weight, against a one-in-five chance of skin symptoms and a higher bill, is the trade the label leaves you to weigh with a prescriber.

If you buy brand semaglutide through a telehealth seller instead, check which product it lists, because Ozempic is a different label from Wegovy. SkinnyRx, Wellorithm and Concierge MD LA list both Wegovy and Ozempic pens; Wellorithm ties its brand price to a three-month plan paid up front. TrimRx, Gala and Push Health list brand Ozempic. None of the listings we recorded names the 7.2 mg strength, so ask before you assume a seller can fill it.

Some sellers split the bill instead of reselling the pen. AgelessRx has NovoCare bill you for Wegovy directly and charges its own monthly monitoring fee on top, so the cost of the pen and the cost of the care arrive as two separate charges.

Insurance is the other route to the pen, though some plans, Cigna among them, treat 7.2 mg as a step after a stretch on 2.4 mg. FitRx and AM Rx both sell a membership whose coordinators pursue insurance approval for Wegovy and Ozempic, among other brands. FitRx says that membership does not include the medication, and AM Rx still requires its membership when insurance covers the drug.

One thing this table is not

Before quoting anything from Table 4, know its inclusion rule. It lists reactions occurring in at least 2% of people and more often than on both 2.4 mg and placebo.[1]

It is built specifically to show what gets worse at the higher dose. Anything equally common at both doses is not in it. So this is a table about the marginal cost of escalating, not a safety profile of the drug, and reading it as one would leave out every reaction that is just as common at 2.4 mg.

For what the doses buy on the other side of that trade, our semaglutide timeline sets out what the trials recorded, and how long side effects last covers the escalation-week pattern.

Frequently Asked Questions

7.2 mg once weekly. The label allows it only after at least four weeks on 2.4 mg that the patient has tolerated, and only where additional weight reduction is clinically indicated, weighing both response and tolerability.
Dysesthesia (abnormal skin sensation), at 22% against 6% at 2.4 mg and 0% on placebo. The label defines it as including allodynia, burning, heightened sensitivity, skin pain and tingling. It is by far the largest increase in the table.
Barely. Nausea goes from 35% at 2.4 mg to 39% at 7.2 mg, and constipation from 19% to 20%. The gastrointestinal effects are largely already priced in at the lower dose; what escalation mainly adds is the skin sensation, and a doubling of hair loss from 3% to 6%.
Often, but not always. Of 288 people on 7.2 mg who had it, 18% had no recovery reported by the end of the trial, and most of them had kept the same dose. Most who paused, cut the dose or stopped did recover, and faster than those who changed nothing. Of 38 who recovered and went back up to 7.2 mg, 17 (45%) had it again, according to the label.
No. The label frames it as an option where further weight reduction is clinically indicated and tolerability allows, not as the end of the ladder or a reward for tolerating 2.4 mg.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Table 4 (adverse reactions at 7.2 mg, N=1,311) and Section 2.1 dosage escalation (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952.
  3. 3.Novo Nordisk FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile PR Newswire, March 19, 2026. 2026. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
  4. 4.Novo Nordisk Wegovy savings offer and NovoCare Pharmacy self-pay pricing NovoCare, accessed October 17, 2026. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html

GLP-1 Overdose: What Happens and What to Do

Most GLP-1 overdoses are dosing mistakes with compounded vials and cause severe nausea and vomiting that can last days. The guidance on the Ozempic, Wegovy, Mounjaro and Zepbound labels, FDA's dosing-error alert, and when to call Poison Help or 911.

10 min read

Does Your GLP-1 Wear Off Before the Next Dose?

Half of each dose is still present when the next one is due. The label puts semaglutide's elimination half-life at roughly seven days, tirzepatide's at about five. That is a slope, not a cliff.

6 min read

How to Take the Wegovy Pill: Water, Timing, Doses and Missed Pills

The Wegovy pill's label directions: first thing in the morning before eating, no more than half a cup of water, a half-hour wait, the 1.5 mg to 25 mg dose steps, what the label says about staying on a low dose, taking it at night, every other day and missed tablets.

7 min read

Is There a Best Time of Day to Inject a GLP-1?

No. The label fixes the weekday and leaves the hour open, food or no food, and separately confirms that both the hour and the injection site can move with no change to the dose.

5 min read

How Many Units Is Your GLP-1 Dose? It Depends on the Vial

A syringe measures volume, a dose is measured in milligrams, and the number connecting them is set by whichever pharmacy filled your vial. Full conversion tables for compounded semaglutide and tirzepatide.

8 min read

Which Zepbound Dose Works Best? 5, 10 and 15 mg Compared in the Trials

In SURMOUNT-1, Zepbound 15 mg averaged 20.9% weight loss, 10 mg 19.5% and 5 mg 15.0%. The step from 10 to 15 mg added 1.4 points. Results, side effects and discontinuation by dose, the 15 mg maximum, and why the label counts 5, 10 and 15 mg as maintenance.

10 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.1

Direct Meds

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →